AstraZeneca PLC
LSE:AZN
Intrinsic Value
The intrinsic value of one
AZN
stock under the Base Case scenario is
19 036.01
GBX.
Compared to the current market price of 10 580 GBX,
AstraZeneca PLC
is
Undervalued by 44%.
The Intrinsic Value is calculated as the average of the two valuation methods:
Fundamental Analysis
AZN Profitability Score
Profitability Due Diligence
AstraZeneca PLC's profitability score is 59/100. The higher the profitability score, the more profitable the company is.
Score
AstraZeneca PLC's profitability score is 59/100. The higher the profitability score, the more profitable the company is.
AZN Solvency Score
Solvency Due Diligence
AstraZeneca PLC's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Score
AstraZeneca PLC's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Balance Sheet Decomposition
AstraZeneca PLC
AZN Capital Structure
AstraZeneca PLC
| Market Capitalization | 164B GBX | |
| Total Debt | 24.3B GBX | |
| Minority Interest | 20M GBX | |
| Preferred Equity | 0 GBX | |
| Cash and Equivalents | 4.5B GBX | |
| Short-Term Investments | 440M GBX | |
| Enterprise Value | 183B GBX | |
Wall St
Price Targets
AZN Price Targets Summary
AstraZeneca PLC
According to Wall Street analysts, the average 1-year price target for
AZN
is 12 262.42 GBX
with a low forecast of 6 741.86 GBX and a high forecast of 18 375 GBX.
Competitive Landscape
AZN Competitors
AstraZeneca PLC
AZN Suppliers & Customers
AstraZeneca PLC
AstraZeneca PLC has 133 key suppliers from 14 countries and 16 industries. The majority of these suppliers are located in the United States of America, with the largest number of suppliers in the Biotechnology industry.
AstraZeneca PLC has 60 key customers from 11 countries and 8 industries. The majority of these customers are located in the United States of America, with the largest number of customers in the Biotechnology industry.
Shareholder Return
AZN Price
AstraZeneca PLC
| Average Annual Return | 16.47% |
| Standard Deviation of Annual Returns | 14.57% |
| Max Drawdown | -13% |
| Market Capitalization | 164B GBX |
| Shares Outstanding | 1 549 529 984 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
AstraZeneca PLC
Country
Industry
Market Cap
Dividend Yield
Description
AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. The company is headquartered in Cambridge, Cambridgeshire and currently employs 83,100 full-time employees. The company went IPO on 2007-09-21. The firm focuses on discovery and development, manufacturing and commercialization of prescription medicines, primarily for the treatment of diseases. The firm is focused on three main therapy areas: Oncology; Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Its pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development. The firm has access to technologies, both internally and through its various collaborations. Its technologies include acoustic tube technology, advanced molecular imaging, cryo-electron microscopy (cryo-EM), functional genomics, multi-omics and AstraZeneca iLab. The Company’s acoustic tube technology helps it to handle and process millions of compounds for biological screening. Its AstraZeneca iLab is its prototype of an automated medicinal chemistry laboratory.
Contact
IPO
Employees
Officers
The intrinsic value of one
AZN
stock under the Base Case scenario is
19 036.01
GBX.
Compared to the current market price of 10 580 GBX, AstraZeneca PLC is Undervalued by 44%.
